Nivolumab or atezolizumab in the second-line treatment of advanced non-small-cell lung cancer? Prognostic index based on real-world data

被引：0
|
作者：
Knetki-Wroblewska, M. [1 ]
Pluzanski, A. [1 ]
Tabor, S. [1 ]
Winiarczyk, K. [1 ]
Zaborowska-Szmit, M. [1 ]
Zajda, K. [1 ]
Zebrowska, A. Janowicz [1 ]
Piorek, A. [1 ]
Badurak, P. [1 ]
Jaskiewicz, P. [1 ]
Kowalski, D. M. [1 ]
Krzakowski, M. J. [1 ]
机构：
[1] Maria Sklodowska Curie Natl Res Inst Oncol, Lung Canc & Chest Tumors Dept, Warsaw, Poland
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1166
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1040P
引用
收藏
页码：S1030 / S1030
页数：1
相关论文
共 50 条
  • [1] Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice
    Knetki-Wroblewska, Magdalena
    Tabor, Sylwia
    Piorek, Aleksandra
    Pluzanski, Adam
    Winiarczyk, Kinga
    Zaborowska-Szmit, Magdalena
    Zajda, Katarzyna
    Kowalski, Dariusz M.
    Krzakowski, Maciej
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (06)
  • [2] Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer
    Rounds, Amanda
    Kolesar, Jill
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (21) : 1851 - 1855
  • [3] Prognostic evaluation and choice of second-line treatment for patients with advanced non-small-cell lung cancer
    Di Maio, Massimo
    Morabito, Alessandro
    Daniele, Gennaro
    Giordano, Pasqualina
    Piccirillo, Maria Carmela
    Costanzo, Raffaele
    Sandomenico, Claudia
    Montanino, Agnese
    Gridelli, Cesare
    Rocco, Gaetano
    Perrone, Francesco
    LUNG CANCER MANAGEMENT, 2012, 1 (01) : 55 - 62
  • [4] Real-world study of lazertinib as second-line or greater treatment in advanced non-small cell lung cancer
    Lim, Jeong Uk
    Kim, Kyuhwan
    Kim, Kyu Yean
    Kang, Hye Seon
    Shin, Ah. Young
    Yeo, Chang Dong
    Kim, Sung Kyoung
    Park, Chan Kwon
    Lee, Sang Haak
    Kim, Seung Joon
    THORACIC CANCER, 2024, 15 (19) : 1513 - 1521
  • [5] REAL-WORLD DATA OF NIVOLUMAB IN NON-SMALL-CELL LUNG CANCER PATIENTS IN GREECE
    Kourlaba, G.
    Kokkotou, E.
    Papaspiliou, A.
    Stefanou, G.
    Stournara, L.
    Syrigos, K.
    VALUE IN HEALTH, 2019, 22 : S435 - S436
  • [6] The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study
    Ohe, Yuichiro
    Yamazaki, Naoya
    Yamamoto, Nobuyuki
    Murakami, Haruyasu
    Yoh, Kiyotaka
    Kitano, Shigehisa
    Hashimoto, Hideyuki
    Murayama, Ayako
    Nakane, Sayuri
    Gemma, Akihiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (06) : 623 - 632
  • [7] Second-line therapy for advanced non-small-cell lung cancer
    Hann C.L.
    Brahmer J.R.
    Current Oncology Reports, 2006, 8 (4) : 243 - 247
  • [8] Prognostic Significance of HALP Score in Second-Line Nivolumab Treatment of Advanced Non-Small Cell Lung Cancer
    Akgul, Fahri
    Gokmen, Ivo
    Gulbagci, Burcu
    Bayrakci, Ismail
    Divriklioglu, Didem
    Bakir Kahveci, Gizem
    Akkus, Aysun Fatma
    Aydin, Tayyip Ilker
    Hacioglu, Bekir
    Erdogan, Bulent
    Topaloglu, Sernaz
    NAMIK KEMAL MEDICAL JOURNAL, 2025, 13 (01): : 6 - 12
  • [9] Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs
    Giuliani, Jacopo
    Bonetti, Andrea
    CLINICAL LUNG CANCER, 2017, 18 (05) : E363 - E365
  • [10] Real-world data on nivolumab treatment of non-small cell lung cancer
    Brustugun, O. T.
    Sprauten, M.
    Helland, A.
    ACTA ONCOLOGICA, 2017, 56 (03) : 438 - 440
12345